Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE
This article was originally published in The Pink Sheet Daily
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.
You may also be interested in...
FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.
Despite the drug’s high price and significant budget impact, NICE has recommended Alexion’s Soliris for aHUS, suggesting the U.K. health technology assessment agency is easing its focus on cost.
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.